Coegin Pharma AB (publ) (NGM:COEGIN)
Sweden · Delayed Price · Currency is SEK 2.370
+0.140 (6.28%)
At close: Nov 6, 2026
Coegin Pharma AB Company Description
Coegin Pharma AB (publ), a biotechnology company, develops and commercializes cosmetic technologies for hair and skin in Sweden.
Its flagship product is Follicopeptide, a patented, clinically developed peptide technology targeting hair thinning; and NPP-4, a cosmetic peptide product designed to enhance skin tone without UV exposure or chemicals.
The company also develops FOL026, a peptide drug candidate for the treatment of myocardial infarction; AVX420, a drug candidate for the treatment of leukemia; and AVX001, a drug candidate for the topical treatment of both actinic keratosis and basal cell carcinoma.
Coegin Pharma AB (publ) was founded in 2005 and is headquartered in Lund, Sweden.
Coegin Pharma AB (publ)
| Country | Sweden |
| Founded | 2005 |
| Industry | Pharmaceutical Preparations |
| Employees | 3 |
| CEO | Jens Eriksson |
Contact Details
Address: Medicon Village Lund, 223 81 Sweden | |
| Phone | 46 72 221 24 21 |
| Website | coeginpharma.com |
Stock Details
| Ticker Symbol | COEGIN |
| Exchange | Nordic Growth Market |
| Fiscal Year | January - December |
| Reporting Currency | SEK |
| ISIN Number | SE0020357754 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Jens Eriksson | Chief Executive Officer |
| Lars Rasmussen | Chief Financial Officer |